Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Irreversible Electroporation on Quality of Life for Patients With Locally Advanced Pancreatic Cancer

NCT02926040 is registered in ClinicalTrials.gov with Insel Gruppe AG, University Hospital Bern as lead sponsor.

NCT NCT02926040
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02926040 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Irreversible Electroporation on Quality of Life for Patients With Locally Advanced Pancreatic Cancer
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Phase
Observational
Overall status
Terminated
Start date
October 31, 2016
Completion date
February 25, 2020
Enrollment
14 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer